Seagate closes exchange of $185.9M exchangeable notes for cash and 2.02M shares

Seagate Technology Holdings plc

Exchanged $185.908M principal of 3.50% Exchangeable Senior Notes due 2028 for $185.908M cash and 2,023,124 ordinary shares.
Exchanges closed May 26-27, 2026; pricing determined over one trading day starting May 21, 2026.
Exchanged notes retired; approximately $185.8M aggregate principal amount of notes remain outstanding unchanged.
Transaction conducted as private placement exempt from registration under Section 4(a)(2) of Securities Act.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-243110
form_type: 8-K
ticker: STX
cik: 0001137789
company_name: Seagate Technology Holdings plc
filed_at: 2026-05-28T12:54:01+00:00
discovered_at: 2026-05-28T13:00:00.339259+00:00
generated_at: 2026-05-28T13:07:57.207671+00:00
sec_items: ["3.02", "8.01", "7.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-243110
json_url: https://secwatch.observer/filing/0001193125-26-243110.json
markdown_url: https://secwatch.observer/filing/0001193125-26-243110.md
text_url: https://secwatch.observer/filing/0001193125-26-243110.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1137789/000119312526243110/0001193125-26-243110-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1137789/000119312526243110/d106085d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01